Sign In
Buy CUE
$26.84
-3.56 (-11.71%)
At Close: Jul 31, 2026
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
04:05pm, Tuesday, 12'th Aug 2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Additional complete response (CR) observed in patient with multiple tumors Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patien
ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC 12-month landmark survival of 88% and mOS of 32 months
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 CUE-401, a first-in-class bispec
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
06:10pm, Monday, 12'th May 2025
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.25 per share a year ago.
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
04:05pm, Monday, 12'th May 2025
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
10:00am, Monday, 05'th May 2025
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
11:05am, Thursday, 01'st May 2025
Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)
06:12pm, Tuesday, 15'th Apr 2025
Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Busine
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
02:00am, Tuesday, 15'th Apr 2025
Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to devel
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
10:23pm, Monday, 14'th Apr 2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Cue Biopharma Announces Proposed Public Offering
05:05pm, Monday, 14'th Apr 2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Cue Biopharma to Host Business Update Call and Webcast
05:02pm, Monday, 14'th Apr 2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
05:00pm, Monday, 14'th Apr 2025
INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
06:16pm, Monday, 31'st Mar 2025
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago.
